|
The financial literature relating to options is daunting, both because of its volume and, in large part, its technical nature - the latter only rendered more obscure by the associated jargon. For those courageous enough to wade into the depths of this literature, frustration will be experienced both in extracting information relevant to pharmaceutical R&D and, even more so, in applying it. Thus, Dr Kerstin M. Bode-Greuel (the author of this report) is unusually well-equipped to act as a guide through the wilderness for the following reasons: |
